Post on 21-Mar-2018
Published By
LIBRARY & INFORMATION CENTRE
INDIAN PHARMACOPOEIA COMMISSION Ministry of Health & F. W., Govt. of India
Ghaziabad (U. P.)
Vol. 2, Issue 12, December 2017
2
Index Contents Page No.
Vol. 2, Issue 12, December 2017
Railway stations and petrol pumps to have generic store all over India
Dainik Jagran 5
India and the future of life sciences innovation
Mint 5
Drug makers pare costs as profitability continues to fall
Mint 7
Seasonal disease, doc strikes leave healthcare in a shambles
Hindustan times 8
Vaccine drive immune to stir
Hindustan times 8
Unlicensed body building supplements may face ban
Hindustan times 9
Who trolled for stand on gaming disorder?
The Times of India 10
Drugs consumables 30-35% of hosp bills, doc fees 10-20%
The Times of India 11
Cancer drug price hiked 15 fold in four years
The Times of India 12
Sun pharma’s US eye drug filing reason to cheer but cautiously
Mint 13
Encephalitis becoming a national problem, says report
Hindustan times 14
Bharti AXA launches smart super health policy
Hindustan times 14
Birth control for problem animals: which drug how to administer it
The Indian Express 15
Lupin drags govt to court over double taxation fear
The Economic Times 16
Sun rises 7% after USFDA nod to dry eye drug
The Economic Times 17
Despite storage India discards 1m blood unit per year
The Times of India 18
3
3-Day pharma meet begins tomorrow
Hindustan times 19
Pharma cong urges centre to end dual control
Hindustan times 20
Aurobindo’d antibiotic API substandard: Maha FDA
The Indian Express 21
Pharma marketing practices code soon
Mint 22
Blockchain pumping new life into old school cos like IBM
The Economic Times 23
Drugmaker ignored over 200 Bad quality test says FDA
The Economic Times 23
Big Pharma desperate for deals agnostic of geographies
The Economic Times 24
Centre to verify claims of states via user feedback
The Economic Times 25
Bringing down the cost of healthcare
The Economic Times 26
37 drugs found sub standard
Dainik Jagran 27
Antibiotic over use is a silent killer
The Times of India 28
IISc: HIV drug elvitegravir lower the efficiency of immune system
The Hindu 29
NCCS’ novel approach improves success rate of bone marrow transplantation
The Hindu 30
IMA tightens the screws on antibiotic prescription
The Hindu 31
Healthcare beyond half the world’s reach, says WHO study
The Times of India 32
Daily Intake of hot tea decrease Glaucoma
Dainik Jagran 33
New health commission get green signal
Dainik Jagran 33
Medical Commission draft ready: Editorial
Dainik Jagran 34
4
Garlic can prevent tumour
Dainik Jagran 35
Ayurvedic dispensary to be shifted soon
Dainik Jagran 36
New Immunotherapy to foght cancer
Dainik Jagran 37
NPPA eases norms for new drug approvals
Mint 38
Regulator fortis kept profit margin as high as 1,737%
The Indian Express 39
Drug controller allows indian firm to conduct phase 1 trial for zika vaccine
The Indian Express 40
Aurobindo, DRL lead race to buy orchid
The Economic Times 41
Pharma cos concerned over double Taxation on old stock of medicines
The Economic Times 42
Indian drug makers may see a sharp rise in FDA inspections
The Economic Times 43
NPPA notifies prices of 65 essential formulations
The Economic Times 44
Indian drug makers may see a sharp rise in inspection
The Economic Times 45
Twitter begins enforcing rules on hateful, abusive content
The Times of India 46
AIIMS GH to consider rotation of dept head
The Times of India 47
With UP as Lab WHO designs a list for safer childbirth
The Times of India 48
Beware price controls on medicine: it will deter pharma industry
The Times of India 49
5
Dated: 29-Dec-2017-Page-2
Dated: 29-Dec-2017-Page-14
India and the future of life sciences innovation KURT STOECKLI, 29 Dec 2017 ZoomBookmarkSharePrintListenTranslate
India is known for many wonderful things. On the international stage, it is recognized as the
fastest-growing economy in the world, and is well-known for its culture, exquisite cuisine and sense of community and family, among many other qualities. One thing it is less known for is the discovery and development of new medicines. I think this will soon change. The Indian pharmaceutical industry is a world leader in bringing generic drugs to the market in a cost-effective way. Additionally, many Western pharmaceutical companies have established small molecule development and manufacturing in India. More recently, Indian pharma companies
have demonstrated the capability to develop biosimilars for global healthcare markets. These activities are highly valuable, providing essential and established medicines at more affordable prices to people around the world.
6
However, having worked for decades in multinational research and development of
new drugs, I think that the future of India will go beyond generics and biosimilars. There are
many attractive features that the existing Indian ecosystem can offer the life sciences industry
and I believe that India will eventually play a critical role in the advancement of innovative medicines. Improvements in genome sequencing have led to a better understanding of what causes and drives the progression of disease. Therapies based on translational strategies rationally target the mechanisms underlying the disease. Precision medicine combines both these ideals, by getting the right drug to the right patient at the right time. It is here that I see opportunities for globally operating Indian pharmaceutical companies to address unmet medical needs worldwide.
Companies that are based in India but have substantial US operations are perfect examples
of such innovators. Such companies are discovering new, cutting-edge precision medicines using state-of-the-art technologies, and hastening exploratory clinical studies in collaboration with major medical centres in India that provide unique access to treatment-naive patients. Public-private partnerships are further unlocking the potential of Indian biomedical research and
development. And people are taking notice. The environment for highly innovative and cost-effective biomedical research has changed markedly. Today, there is much more time and cost pressure on the research and development of innovative medicines, particularly with regard to preclinical and early clinical research.
Big Western pharma is facing challenges in this regard. While the industry has the capacity
and capability to develop drugs and commercialize them, and the economies of scale to do so
profitably, these organizations often lack the agility and flexibility to innovate constantly in the increasingly competitive realm of life sciences discovery. Many of the largest pharmaceutical companies in the world are relying on early-stage collaboration with start-up biotech firms and established academic labs to manage the inherently risky prospect of drug innovation. This type of early innovation will always be high-risk, but more importantly, will face progressive challenges of managing that risk in a nimble way. Essentially, it’s about finding methods and processes that accelerate success and help unsuccessful projects “fail faster”. The key to nimble
risk management will flow from innovation hypotheses grounded in translational medicine, patient stratification and value propositions that convince investors, payers and regulators of the potential improvement and superiority in standards of care.
Sixty years ago, the total number of physicians in India was less than 50,000; today there
has been a 16-fold increase to nearly 800,000 registered medical practitioners. Public health
centres, the foundation of rural healthcare in the country, have increased from less than 100 to
more than 23,000. This explosive growth is fertile ground for thought leaders, investors, regulators and medical centres to collaborate on developing the capabilities to nurture the type of start-up environment that will focus on innovation and better ways of healthcare delivery, with an eye on long-run rather than short-term profitability.
To capitalize on these opportunities, I think there are a number of steps that India can
take. For example, incentives for start-up biotech firms, and commitment to rigorous global compliance standards that help increase trust in the Indian life sciences industry. These trends are under way globally, but, in some respects, have yet to be initiated by experts with roots in India. Thought leaders must embrace a mindset that celebrates risk-taking and shows unwavering commitment to long-term objectives. By making investments in risky but nonetheless highly valuable emerging science, the global life sciences landscape will undergo an evolution as India transforms itself into a centre of excellence.
We have seen monumental progress in science and technology in recent years, most
notably in the field of immuno-oncology for some of the hardest-to-treat cancers. These innovations didn’t happen in isolation, but emerged from collaborative networks. Today,
innovation occurs in a global village, not in a single country. With so much to offer the life sciences, India is poised to become a dominant player. The potential for this groundswell to
materialize is happening today. It’s exciting to be a part of it. Kurt Stoeckli is president and chief scientific officer at Glenmark Pharmaceuticals.
7
Dated: 29-Dec-2017-Page-8
8
Dated: 29-Dec-2017-Page-3
9
Dated: 29-Dec-2017-Page-13
10
Dated: 29-Dec-2017-Page-17
11
Dated: 29-Dec-2017-Page-11
12
Dated: 29-Dec-2017-Page-18
13
Dated: 28-Dec-2017-Page-4
14
Dated: 28-Dec-2017-Page-2
15
Dated: 27-Dec-2017-Page-13
16
Dated: 28-Dec-2017-Page-7
17
Dated: 28-Dec-2017-Page-10
18
Dated: 28-Dec-2017-Page-13
19
(Chandigarh)
Dated: 21-Dec-2017-Page-2
20
Dated: 25-Dec-2017-Page-2
21
Dated: 27-Dec-2017-Page-21
22
Dated: 25-Dec-2017-Page-5
23
Dated: 27-Dec-2017-Page-6
Dated: 27-Dec-2017-Page-11
24
Dated: 25-Dec-2017-Page-12
25
Dated: 25-Dec-2017-Page-13
26
Dated: 23-Dec-2017-Page-10
27
Dated: 14-Dec-2017-Page-17
28
Dated: 22-Dec-2017-Page-1
29
Dated: 17-Dec-2017-Page-14
30
Dated: 17-Dec-2017-Page-14
31
Dated: 17-Dec-2017-Page-10
32
Dated: 15-Dec-2017-Page-18
33
Dated: 16-Dec-2017-Page-13
Dated: 16-Dec-2017-Page-1
34
Dated: 16-Dec-2017-Page-1
35
Dated: 18-Dec-2017-Page-10
36
Dated: 14-Dec-2017-Page-II (Ghaziabad)
37
Dated: 12-Dec-2017-Page-13
38
Dated: 21-Dec-2017-Page-6
39
Dated: 16-Dec-2017-Page-5
40
Dated: 19-Dec-2017-Page-2
41
Dated: 18-Dec-2017-Page-16
42
Dated: 19-Dec-2017-Page-18
43
Dated: 18-Dec-2017-Page-16
44
Dated: 19-Dec-2017-Page-18
45
Dated: 18-Dec-2017-Page-16
46
Dated: 19-Dec-2017-Page-20
47
Dated: -Dec-2017-Page
48
Dated: 21-Dec-2017-Page19
49
Dated: 16-Dec-2017-Page22
*******************************************